Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week Low - What's Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price hit a new 52-week low on Wednesday . The company traded as low as $18.00 and last traded at $18.05, with a volume of 6643 shares changing hands. The stock had previously closed at $18.29.

Analyst Ratings Changes

DNTH has been the subject of several research reports. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a "buy" rating for the company. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Guggenheim reiterated a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $54.33.

Dianthus Therapeutics Trading Up 0.6 %

The business has a 50-day moving average of $21.91 and a 200 day moving average of $24.26. The firm has a market capitalization of $642.18 million, a P/E ratio of -8.00 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. As a group, research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNTH. TCG Crossover Management LLC bought a new position in shares of Dianthus Therapeutics in the 4th quarter worth $32,735,000. Braidwell LP raised its position in Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares in the last quarter. Vestal Point Capital LP lifted its stake in Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock worth $23,435,000 after purchasing an additional 680,000 shares during the last quarter. State Street Corp increased its position in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company's stock valued at $22,483,000 after purchasing an additional 413,425 shares during the last quarter. Finally, Octagon Capital Advisors LP raised its holdings in shares of Dianthus Therapeutics by 20.8% during the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after buying an additional 363,500 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.